Novo Fights Back! 21% Weight Loss and the Future of GLP-1s

Novo Nordisk is fighting back, and this week’s GLP-1 news shows just how quickly the obesity treatment market is changing. Christopher and Laraine Durham break down new CagriSema results showing 21% average weight loss, including how the drug compared with tirzepatide in different trials and what the numbers actually mean for patients. They also look at Canada’s growing generic semaglutide market, a new study exploring semaglutide and aging, Eli Lilly’s next generation of obesity drugs, and Novo’s multibillion-dollar push toward pills, combination treatments, and the future of GLP-1 care. Plus, Illinois Governor JB Pritzker reveals his own 80-pound GLP-1 weight loss, CVS creates dedicated GLP-1 sections in stores, UK pharmacies push the boundaries on who may qualify for treatment, and Novo walks away from a once-monthly semaglutide deal. The GLP-1 market is moving beyond the first generation of Wegovy and Zepbound. The next fight is about greater weight loss, new mechanisms, easier dosing, better access, and what these treatments could look like five or ten years from now. +++++++++++++++++++++++++++++++++++++++ Start your weight loss journey today! We use Mochi Health: https://app.joinmochi.com/eligibility... Use Laraine’s code for $40 off: QIYGO8. Get your Hume BodyPod today and use our exclusive Downsized code for up to 20% total savings! 👉 Use our Code: THEDOWNSIZED Link to purchase: https://humehealth.com//discount/THED... SHOP OUR AMAZON STORE: https://a.co/d/0gGe1MYq BOOK THE DOWNSIZED AT SEA CRUISE 2027: https://thedownsized.org/downsized-at... GET YOUR DOWNSIZED LIVE! ON TOUR TICKETS: https://thedownsized.org/meet-ups/ DOWNSIZED WEBSITE: https://thedownsized.org/ JOIN CLUB DOWNSIZED:    / @thedownsized   FOR SPONSORSHIPS, BRAND DEALS & COLLABS: https://thedownsized.org/contact/ +++++++++++++++++++++++++++++++++++++++ 00:00 Novo Fights Back! 21% Weight Loss and the Future of GLP-1s 02:40 CagriSema vs. Tirzepatide: New Head-to-Head Results 07:12 Canada Approves More Generic Semaglutide 10:15 Illinois Governor Reveals 80-Lb GLP-1 Weight Loss 13:14 Could Semaglutide Slow Aging? New Mouse Study 15:14 CVS Builds New GLP-1 Sections in Stores 17:49 UK Pharmacies Offering GLP-1s at BMI 25 20:10 Eli Lilly Drops an Experimental Obesity Drug 21:42 Lilly’s Next Triple-Pathway Obesity Drug 24:16 Novo Bets $1.4 Billion on New Oral Obesity Drugs 27:01 Novo Drops Its Once-Monthly Semaglutide Deal 29:41 Novo’s Plan for the Next Generation of Obesity Drugs 31:47 Downsized Live on Tour